

RESEARCH

Preparing for Tomorrow Innovating and Evolving



Wockhardt Research Center, India developing ANDA / MA products for the US & European markets

DISTINCT ACHIEVEMENT IN BIOTECHNOLOGY SPACE

Having received DCGI permission, Wockhardt is ready to launch insulin analogue, Glargine in the Indian market. This is a 'long acting' recombinant insulin with a promising future. Wockhardt is next only to the originator in the world to have got this developed.

WOSULIN CLINICAL TRIALS TO PROGRESS IN US AND EUROPE

Our first BIO-IND for recombinant insulin injectables (Wosulin) is approved in the US for clinical trials. The same will follow soon for Europe as well. These consequential achievements have opened doors to the marketing of Wosulin within a few years in the highly regulated markets, unleashing a huge market potential for the product.

Considering our rich portfolio of products and our early mover advantage, we are slated to account

for \$20 billion of the total \$ 30 billion off-patent opportunity, over the next 10 years.

INCREASING REGULATORY APPROVALS OF WOSULIN FROM ROW MARKETS

Wosulin goes forward in ROW (Rest of the World) markets. Leveraging our standing in the biotechnology sphere, we have already ventured into several international markets. **We received 45 regulatory approvals for recombinant insulin (Wosulin) in the ROW markets, taking our total of registered biotechnology product to 73.**

BUILDING GATEWAYS TO THE GLOBAL MARKET

With our well-thought-out Biosimilar strategy, we are ready to take the opportunity into the global biotechnology market. We plan to enter into strategic alliances for our biotech products.



PHARMA RESEARCH IN THE ACTIVE MODE

On the Wockhardt Pharma Research front, the year 2007 saw receipt of highest number of ANDA approvals - 13 and 32 ANDA/MA filings were undertaken. Moreover, 204 patents were also filed making the research pipeline strong to leverage growth for the company.

NEW CHEMICAL ENTITY, WCK-2349 CLEARED FOR PHASE - I CLINICAL TRIALS

Backed by our robust R&D setup, we have traversed a significant mile in New Drug Discovery program.

We have received the DCGI clearance of IND application to initiate Phase - I Clinical Trials of WCK-2349. Also, our WCK-771 has successfully completed Phase II clinical trials on humans and now gets ready for the next phase of Clinical Trials.



Wockhardt Research Heads in discussion